NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17.
NorthLinks Bio has raised $34.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2026.
NorthLinks Bio's investors include RA Capital Management.
NorthLinks Bio is headquartered in Boston, United States.
NorthLinks Bio is a clinical-stage biopharmaceutical company developing HEX17.
NorthLinks Bio is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"NorthLinks Bio — Funding & Investors." VCBacked, June 23, 2026, https://www.vcbacked.co/company/northlinks-bio. Accessed August 15, 2026.
VCBacked. (2026). NorthLinks Bio — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/northlinks-bio
{{cite web |title=NorthLinks Bio — Funding & Investors |url=https://www.vcbacked.co/company/northlinks-bio |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated